SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study

Guijarro, Carlos; Galán, Isabel Moratilla; Martínez-Ponce, Diana; Pérez‐Fernández, Elia; Goyanes, M.J.; Castilla, Virgilio; Velasco, María

doi:10.1016/j.cmi.2021.06.026

Cited by 11 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review based on studies published from January to August 2021 with eight studies based on surveillance of HCW populations reported the effectiveness of the complete vaccination with Comirnaty, Moderna, and Vaxzevria vaccines of a maximum of 86% [ 9 , 10 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. Our study showed the lowest risk of COVID-19 events in the vaccinated and booster groups and during a longer follow-up period.…”

Section: Discussionmentioning

confidence: 99%

The Dynamic Risk of COVID-19-Related Events in Vaccinated Healthcare Workers (HCWs) from a Tertiary Hospital in Bucharest, Romania: A Study Based on Active Surveillance Data

Chivu,

Crăciun,

Pițigoi

et al. 2024

Vaccines

View full text Add to dashboard Cite

Our study describes the frequency and severity of COVID-19 in HCWs and estimates the dynamic risk of COVID-19-related events. We actively surveyed all HCWs from a tertiary infectious disease hospital from 26 February 2020 to 31 May 2023. Of 1220 HCWs, 62.9% (767) had at least one COVID-19 episode. The under 29 years (p = 0.0001) and 40–49 years (p = 0.01) age groups, nurses (p = 0.0001), and high-risk departments (p = 0.037) were characteristics significantly more frequent in HCWs with COVID-19 history. A higher percentage of boosters (53.2%; p < 0.0001) were registered in the uninfected group. The second episode of COVID-19 was significantly milder than the first. Data regarding clinical outcomes from 31 January 2021 to 31 May 2023 were analyzed in a follow-up study to determine the risk of COVID-19-related events. The Cox regression analysis revealed that HCWs with booster shots had a lower risk of COVID-19 across all events, symptomatic events, and moderate to severe events as adjusted hazard ratio (aHR) were: 0.71 (95%CI: 0.54–0.96), 0.23 (95%CI: 0.12–0.46), and 0.17 (95%CI: 0.07–0.43), respectively. Within the vaccinated subgroup, the HCWs with hybrid immunity and booster had aHR for all followed-up events of 0.42 (95%CI: 0.30–0.58), for symptomatic events of 0.52 (95%CI: 0.36–0.74), and 0.15 (95%CI: 0.03–0.66) for moderate to severe events. The risk of COVID-19 clinical events was lower for HCWs with at least one booster than those completely vaccinated.

show abstract

Section: Discussionmentioning

confidence: 99%

The Dynamic Risk of COVID-19-Related Events in Vaccinated Healthcare Workers (HCWs) from a Tertiary Hospital in Bucharest, Romania: A Study Based on Active Surveillance Data

Chivu,

Crăciun,

Pițigoi

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…Characteristics of all 50 published articles and preprints that assessed VE are provided in Table 1 . Results are presented in alphabetic order by study author [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 ] under the headings Published Articles and Preprints. Vaccine effectiveness estimates for identified and circulating variants are also provided.…”

Section: Resultsmentioning

confidence: 99%

COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January–30 June 2021)

et al. 2022

View full text Add to dashboard Cite

Observational studies are needed to demonstrate real-world vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outcomes. Our objective was to conduct a review of published SARS-CoV-2 VE articles, supplemented by preprints, during the first 6 months of COVID-19 vaccine availability. This review compares the effectiveness of completing the primary COVID-19 vaccination series against multiple SARS-CoV-2 disease presentations and disease severity outcomes in three population groups (general population, frontline workers, and older adults). Four hundred and seventy-one published articles and 47 preprints were identified. After title and abstract screening and full article review, 50 studies (28 published articles, 22 preprints) were included. VE results were reported for five COVID-19 vaccines and four combinations of COVID-19 vaccines. VE results for BNT162b2 were reported in 70.6% of all studies. Seventeen studies reported variant specific VE estimates; Alpha was the most common. This comprehensive review demonstrates that COVID-19 vaccination is an important tool for preventing COVID-19 morbidity and mortality among fully vaccinated persons aged 16 years and older and serves as an important baseline from which to follow future trends in COVID-19 evolution and effectiveness of new and updated vaccines.

show abstract

“…The first COVID-19 vaccine (Pfizer-BioNTech COVID-19 Vaccine; BNT162b2) was approved by the FDA for emergency use authorization and subsequently for the Moderna COVID-19 vaccine (mRNA-1273). These vaccines provide ~90% effectiveness prevention of infection for full vaccination and 80% for partial vaccination, [270][271][272][273] However, neutralization antibodies against the SARS-CoV-2 Omicron variant are undetectable in the sera of most mRNA-1273 or BNT162b recipients, while additional mRNA vaccine dose seems to improve the neutralization. 274 SARS-CoV-2 consists of structural proteins, spike (S), nucleocapsid (N), envelope (E), and membrane (M).…”

Section: Cationic Nanoemulsionmentioning

confidence: 99%

“…288 Several SARS-CoV-2 variants have emerged with the global COVID-19 pandemic. 289 Fortunately, chimeras of the viral S protein were developed to prevent SARS-CoV-2 variants, 270 and BNT162b2 and mRNA-1273 can still effectively prevent SARS-CoV-2 variants infections, including Delta (B.1.617.2), Alpha (B.1.1.7) and Gamma (P.1) variants in adults. 272,290,291 Interestingly, there is a large difference in the mRNA dosages of COVID-19 mRNA vaccines.…”

Section: Cationic Nanoemulsionmentioning

confidence: 99%

mRNA-based therapeutics: powerful and versatile tools to combat diseases

Qin

Tang

Chen

et al. 2022

Sig Transduct Target Ther

259

168

View full text Add to dashboard Cite

The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide range of incurable diseases. Recent rapid advances in biotechnology and molecular medicine have enabled the production of almost any functional protein/peptide in the human body by introducing mRNA as a vaccine or therapeutic agent. This represents a rising precision medicine field with great promise for preventing and treating many intractable or genetic diseases. In addition, in vitro transcribed mRNA has achieved programmed production, which is more effective, faster in design and production, as well as more flexible and cost-effective than conventional approaches that may offer. Based on these extraordinary advantages, mRNA vaccines have the characteristics of the swiftest response to large-scale outbreaks of infectious diseases, such as the currently devastating pandemic COVID-19. It has always been the scientists’ desire to improve the stability, immunogenicity, translation efficiency, and delivery system to achieve efficient and safe delivery of mRNA. Excitingly, these scientific dreams have gradually been realized with the rapid, amazing achievements of molecular biology, RNA technology, vaccinology, and nanotechnology. In this review, we comprehensively describe mRNA-based therapeutics, including their principles, manufacture, application, effects, and shortcomings. We also highlight the importance of mRNA optimization and delivery systems in successful mRNA therapeutics and discuss the key challenges and opportunities in developing these tools into powerful and versatile tools to combat many genetic, infectious, cancer, and other refractory diseases.

show abstract

SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study

Cited by 11 publications

References 12 publications

The Dynamic Risk of COVID-19-Related Events in Vaccinated Healthcare Workers (HCWs) from a Tertiary Hospital in Bucharest, Romania: A Study Based on Active Surveillance Data

The Dynamic Risk of COVID-19-Related Events in Vaccinated Healthcare Workers (HCWs) from a Tertiary Hospital in Bucharest, Romania: A Study Based on Active Surveillance Data

COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January–30 June 2021)

mRNA-based therapeutics: powerful and versatile tools to combat diseases

Contact Info

Product

Resources

About